Jiang, J and Zheng, X and Xu, X and Zhou, Q and Yan, H and Zhang, X and Lu, B and Wu, C and Ju, J
(2011)
Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
PLoS ONE, 6 (8).
Abstract
Background: The goal of this study is to evaluate the effectiveness of S-1/Oxaliplatin vs. Doxifluridine/Oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in gastric cancer patients. The expression of candidate miRNAs was quantified from fifty-five late stage gastric cancer FFPE specimens. Experimental Design: Gastric cancer patients with KPS>70 were recruited for the trial. The control group was treated with 400 mg/twice/day Doxifluridine plus i.v. with Oxaliplatin at 130 mg/m 2/first day/4 week cycle. The testing group was treated with S-1 at 40 mg/twice/day/4 week cycle plus i.v. with Oxaliplatin at 130 mg/m 2/first day/4 week cycle. Total RNAs were extracted from normal and gastric tumor specimens. The levels of miRNAs were quantified using real time qRT-PCR expression analysis. Results: The overall objective response rate (CR+PR) of patients treated with S-1/Oxaliplatin was 33.3% (CR+PR) vs. 17.6% (CR+PR) with Doxifluridine/Oxaliplatin for advanced stage gastric cancer patients. The average overall survival for patients treated with S-1/Oxaliplatin was 7.80 month vs. 7.30 month with patients treated with Doxifluridine/Oxaliplatin. The expression of miR-181b (P = 0.022) and miR-21 (P = 0.0029) was significantly overexpressed in gastric tumors compared to normal gastric tissues. Kaplan-Meier survival analysis revealed that low levels of miR-21 expression (Log rank test, hazard ratio: 0.17, CI = 0.06-0.45; P = 0.0004) and miR-181b (Log rank test, hazard ratio: 0.37, CI = 0.16-0.87; P = 0.018) are closely associated with better patient's overall survival for both S-1 and Doxifluridine based regimens. Conclusion: Patients treated with S-1/Oxaliplatin had a better response than those treated with Doxifluridine/Oxaliplatin. miR-21 and miR-181b hold great potential as prognostic biomarkers in late stage gastric cancer. © 2011 Jiang et al.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Published |
Creators/Authors: |
Creators | Email | Pitt Username | ORCID |
---|
Jiang, J | | | | Zheng, X | | | | Xu, X | | | | Zhou, Q | | | | Yan, H | | | | Zhang, X | | | | Lu, B | binfeng@pitt.edu | BINFENG | | Wu, C | | | | Ju, J | | | |
|
Contributors: |
Contribution | Contributors Name | Email | Pitt Username | ORCID |
---|
Editor | Blagosklonny, Mikhail V. | UNSPECIFIED | UNSPECIFIED | UNSPECIFIED |
|
Date: |
24 August 2011 |
Date Type: |
Publication |
Journal or Publication Title: |
PLoS ONE |
Volume: |
6 |
Number: |
8 |
DOI or Unique Handle: |
10.1371/journal.pone.0023271 |
Schools and Programs: |
School of Medicine > Immunology |
Refereed: |
Yes |
MeSH Headings: |
Antineoplastic Agents--pharmacology; Antineoplastic Agents--therapeutic use; Antineoplastic Combined Chemotherapy Protocols--pharmacology; Antineoplastic Combined Chemotherapy Protocols--therapeutic use; Drug Combinations; Female; Floxuridine--pharmacology; Floxuridine--therapeutic use; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; MicroRNAs--genetics; MicroRNAs--metabolism; Middle Aged; Organoplatinum Compounds--pharmacology; Organoplatinum Compounds--therapeutic use; Oxonic Acid--pharmacology; Oxonic Acid--therapeutic use; Prognosis; Stomach Neoplasms--diagnosis; Stomach Neoplasms--drug therapy; Stomach Neoplasms--genetics; Tegafur--pharmacology; Tegafur--therapeutic use; Treatment Outcome |
Other ID: |
NLM PMC3158077 |
PubMed Central ID: |
PMC3158077 |
PubMed ID: |
21876743 |
Date Deposited: |
05 Sep 2012 19:04 |
Last Modified: |
22 Jun 2021 13:56 |
URI: |
http://d-scholarship.pitt.edu/id/eprint/13889 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
|
View Item |